Ralph Schiess
Vermogen: 190 $ op 31-05-2026
Vermogen: 190 $ op 31-05-2026
Ralph Schiess was the founder of Proteomedix AG, founded in 2010, and held the title of Chief Executive Officer from 2023 to 2025.
Former job includes Chief Executive & Science Officer at Onconetix, Inc. from 2024 to 2025.
Education includes graduate degree from the University of Zurich and doctorate from the Swiss Federal Institute of Technology.
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
ONCONETIX INC 0,01% | 13-03-2026 | 158 ( 0,01% ) | 190 $ | 31-05-2026 |
| Bedrijven | Functie | Einde |
|---|---|---|
Proteomedix AG
Proteomedix AG BiotechnologyHealth Technology Operates as a private, commercial-stage diagnostics oncology company | Algemeen Directeur | 31-05-2025 |
| ONCONETIX, INC. | Algemeen Directeur | 24-02-2025 |
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
| Bedrijven in privébezit | 4 |
|---|---|
University of Zurich
University of Zurich Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Swiss Federal Institute of Technology
Swiss Federal Institute of Technology Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Proteomedix AG
Proteomedix AG BiotechnologyHealth Technology Operates as a private, commercial-stage diagnostics oncology company | Health Technology |
Onconetix, Inc.
Onconetix, Inc. Pharmaceuticals: MajorHealth Technology Develops oncology drugs and diagnostic test for cancers | Health Technology |
Kies jouw editie
Alle financiële informatie op nationaal niveau